IQVIA (NYSE:IQV) Stock Sale Disclosed by Rep. Kevin Hern

Posted by Patrick Bannon on Sep 29th, 2026

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in IQVIA stock on September 8th. The trade occurred in the Representative’s “GABRIELLE ASHTYN HERN TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

IQVIA Stock Down 1.6%

IQVIA stock traded down $4.38 during mid-day trading on Tuesday, reaching $266.58. The stock had a trading volume of 124,975 shares, compared to its average volume of 1,724,784. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The stock’s 50-day simple moving average is $250.32 and its 200-day simple moving average is $203.63. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $277.40. The firm has a market capitalization of $43.88 billion, a PE ratio of 33.11, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same period in the previous year, the company posted $2.81 EPS. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.56 EPS for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, insider W. Richard Staub sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the sale, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This represents a 57.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,581 shares of company stock valued at $3,796,021 in the last 90 days. 1.70% of the stock is owned by insiders.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently made changes to their positions in the business. Apella Capital LLC increased its stake in IQVIA by 5.1% in the 1st quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after buying an additional 58 shares during the period. Breakwater Capital Group increased its holdings in IQVIA by 3.2% during the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after buying an additional 64 shares during the period. First Growth Capital LLC lifted its holdings in IQVIA by 3.2% during the first quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock worth $375,000 after buying an additional 68 shares during the period. Root Financial Partners LLC grew its stake in IQVIA by 31.0% in the fourth quarter. Root Financial Partners LLC now owns 296 shares of the medical research company’s stock valued at $67,000 after purchasing an additional 70 shares during the last quarter. Finally, Chicago Partners Investment Group LLC lifted its position in IQVIA by 1.5% during the first quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock valued at $812,000 after acquiring an additional 70 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IQV has been the topic of several research analyst reports. Weiss Ratings upgraded IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday. Truist Financial reaffirmed a “buy” rating and set a $329.00 price target (up from $300.00) on shares of IQVIA in a research report on Monday. JPMorgan Chase & Co. lifted their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Stifel Nicolaus upped their price objective on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Finally, Royal Bank Of Canada lifted their target price on shares of IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $257.75.

Get Our Latest Report on IQVIA

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.